The Mitochondrial Peptide Revolution: SS-31, MOTS-c, and Humanin

For decades, mitochondria were understood as energy organelles. The site of oxidative phosphorylation and ATP synthesis. The discovery that the mitochondrial genome encodes functional signaling peptides has substantially revised that picture. Mitochondria-derived peptides (MDPs) now constitute a recognized class of bioactive molecules with roles in stress response, metabolism, and aging that are only beginning to be characterized.

Three MDPs have drawn most of the research attention. SS-31 (elamipretide) is synthetic but targets the inner mitochondrial membrane. MOTS-c is encoded by the 12S rRNA region of mtDNA. Humanin was the first identified true MDP. Together they illustrate distinct but complementary aspects of how mitochondria signal to the rest of the cell and organism.

SS-31 (Elamipretide): Cardiolipin Stabilizer in Clinical Trials

SS-31 isn't a mitochondria-encoded peptide. It's a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto and Peter Schiller at Weill Cornell, designed to target the inner mitochondrial membrane. The mechanism centers on cardiolipin: the signature phospholipid of the inner mitochondrial membrane that helps organize the electron transport chain supercomplexes and maintain cristae morphology.

In aged and diseased mitochondria, cardiolipin undergoes peroxidation and reorganization. Cristae architecture collapses and ETC efficiency drops. SS-31 binds cardiolipin electrostatically, stabilizing the membrane and preserving cytochrome c function. The result is improved ATP production, reduced reactive oxygen species, and maintained membrane potential, all without uncoupling the proton gradient.

• Heart failure with preserved ejection fraction (HFpEF): Phase II/III clinical trials; one of the most promising investigational agents for this condition, which has no approved disease-modifying therapy
• Barth syndrome: Orphan designation; Phase II trial showed significant improvement in exercise capacity in this rare pediatric mitochondrial disease
• Renal ischemia-reperfusion injury: Protective effects in multiple preclinical models; potential application in cardiac surgery and transplantation
• Primary mitochondrial myopathy: Phase II trial data showed improvements in distance walked and fatigue measures

Stealth BioTherapeutics conducted multiple clinical trials of SS-31 before encountering financial difficulties. The compound remains in development. Importantly, SS-31's clinical development has generated the most robust human safety and pharmacokinetic data of any MDP, making it the best-characterized in terms of human translation.

MOTS-c: The Exercise Mimetic

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) was identified in 2015 by Pinchas Cohen's group at USC as a 16-amino acid peptide encoded in an open reading frame within the 12S rRNA gene of human mitochondrial DNA. The discovery was conceptually important: the mitochondrial genome had not been thought to encode short signaling peptides, making MOTS-c evidence of a previously unknown mitochondrial communication modality.

MOTS-c is an exercise-mimetic mitochondrial peptide that regulates metabolic homeostasis and age-dependent insulin resistance. Physical exercise increases circulating MOTS-c, and exogenous MOTS-c treatment reverses diet-induced and age-dependent insulin resistance in mice.

— Lee C et al., Cell Metabolism, 2015

Under metabolic stress, MOTS-c translocates to the nucleus and regulates nuclear gene expression via AMPK activation. It inhibits the folate cycle, altering one-carbon metabolism toward antioxidant responses. Physiologically, circulating MOTS-c levels rise during exercise, drop with aging and metabolic disease, and correlate with insulin sensitivity. The 2021 finding that MOTS-c rises specifically during endurance exercise and is directly associated with exercise-induced metabolic benefits has positioned it as a candidate exercise mimetic — a compound that could partially replicate metabolic benefits of physical activity in sedentary or disabled individuals.

A follow-up study published in 2021 found MOTS-c treatment in old mice not only reversed insulin resistance but also improved physical performance, grip strength, and coordination — consistent with a reversal of age-related mitochondrial dysfunction rather than a simple glucose-lowering effect. Human studies are in early stages.

Humanin: The First MDP and Alzheimer's Connection

Humanin was discovered serendipitously in 2001 by Nishimoto et al. at Osaka University, while screening a cDNA library constructed from Alzheimer's-resistant brain tissue. The 24-amino acid peptide, encoded in an open reading frame within the 16S rRNA of mtDNA, was found to protect neurons from Alzheimer's-related apoptotic cell death induced by mutant presenilin-2, APP, and amyloid-beta.

Humanin acts through multiple mechanisms: it binds IGFBP-3, displacing it from the nucleus and preventing IGFBP-3-mediated apoptosis; activates gp130/JAK/STAT3 signaling via a tri-molecular receptor complex; and directly inhibits BAX-mediated mitochondrial outer membrane permeabilization. This anti-apoptotic profile, combined with its mitochondrial origin, makes Humanin uniquely positioned at the intersection of mitochondrial dysfunction and neurodegeneration.

• Circulating levels and aging: Plasma humanin declines approximately 60% between young adulthood and old age in both rodents and humans
• Centenarian offspring: Children of centenarians (individuals who lived past 100) show higher circulating humanin levels than age-matched controls — one of few molecular markers associated with familial longevity
• Alzheimer's disease: Humanin levels are lower in the brains and CSF of Alzheimer's patients versus cognitively normal age-matched controls
• Metabolic effects: Like MOTS-c, humanin improves insulin sensitivity and reduces hepatic glucose production in rodent models
• Cancer: Humanin has antiapoptotic effects in normal cells but some studies show pro-apoptotic activity in cancer cells — the mechanism difference remains incompletely understood

Implications for Aging Research and Current Limitations

The MDP field is notable for its integrative framing: rather than targeting a single pathway, MDPs appear to act as systemic stress-response coordinators — sensed by mitochondria and broadcast to the rest of the cell and organism through peptide signaling. The common thread across SS-31, MOTS-c, and humanin is decline with aging and recovery in models of age-related disease.

The central open question — whether exogenous supplementation can rescue endogenous MDP signaling at physiologically meaningful concentrations in humans — remains unanswered for MOTS-c and Humanin (SS-31 is further advanced in clinical development). Key outstanding issues include bioavailability by non-injectable routes, tissue distribution, optimal dosing, and long-term safety. The anti-apoptotic mechanisms of Humanin in particular require careful evaluation in oncology contexts before clinical use.

Despite these limitations, MDPs represent one of the most scientifically grounded areas of longevity research. Not because the compounds are proven, but because the underlying biology (mitochondrial decline as a driver of aging) is well-established, and the connection between endogenous MDP levels and longevity phenotypes in human populations gives the research an unusual degree of translational plausibility compared to many other longevity interventions.

Questions and answers

Is SS-31 a mitochondria-derived peptide?

No. SS-31, also known as elamipretide, is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornell and designed to target the inner mitochondrial membrane. MOTS-c and humanin are the mitochondria-encoded peptides. SS-31 is grouped with them by mechanism rather than by origin.

How does SS-31 work?

Through cardiolipin, the signature phospholipid of the inner mitochondrial membrane that helps organise the electron transport chain supercomplexes and maintain cristae morphology. In aged and diseased mitochondria cardiolipin undergoes peroxidation and reorganisation. SS-31 binds cardiolipin electrostatically, stabilising the membrane and preserving cytochrome c function without uncoupling the proton gradient.

Why was the discovery of MOTS-c conceptually important?

Because the mitochondrial genome had not been thought to encode short signalling peptides. MOTS-c was identified in 2015 by Pinchas Cohen's group at USC as a 16 amino acid peptide encoded in an open reading frame within the 12S rRNA gene of human mitochondrial DNA, making it evidence of a previously unknown mitochondrial communication modality.

What is the central unanswered question in this field?

Whether exogenous supplementation can rescue endogenous signalling at physiologically meaningful concentrations in humans. That remains unanswered for MOTS-c and humanin, with SS-31 further advanced in clinical development. Outstanding issues include bioavailability by non-injectable routes, tissue distribution, dosing and long-term safety, and humanin's anti-apoptotic mechanism in particular requires careful evaluation in oncology.